MURA 250117 5.00C (MURA250117C5000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

MURA250117C5000

Watchlist

0.04
0.000.00%

15min DelayClose Jan 8 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Optimistic Buy Rating for Mural Oncology Plc Driven by Promising Pipeline Developments and Financial Stability
TipRanks05:36 ET · Ratings
Mural Oncology Achieves 75% OS Events for ARTISTRY-7 Trial and Extends Cash Runway Through Q1 2026
Benzinga01:57 ET
Express News | Mural Oncology PLC -Company Extends Cash Runway Projection Into Q1 2026 Through Operational Efficiencies
Reuters16:42 ET
Mural Oncology Updates on Nemvaleukin Trials and Expands Development Pipeline With New Candidates
Quiver Quantitative16:12 ET
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
GlobeNewswire16:00 ET
Mural Oncology Grants Stock Options and Restricted Stock Units to New Employees as Part of 2024 Inducement Plan
Quiver QuantitativeDec 3, 2024 16:21 ET

Comments

Jaguar8

15 hours ago

NEWS

$Mural Oncology (MURA.US)$
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
Thursday, 9th January at 4:00 pm
Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma
Preliminary data readouts for less-frequent intravenous dosing of nemvaleukin in patients with cutaneous melanoma expected in 1H 2025 for monotherapy, with patient enrollment...

Teddy123

Nov 20, 2024 17:49

Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for Im

$Mural Oncology (MURA.US)$
Mural Oncology's Cancer Drug Shows 33% Response Rate in Melanoma Trial Data | MURA Stock News

Jaguar8

Nov 20, 2024 15:19

NEWS

$Mural Oncology (MURA.US)$
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
Mural Oncology has published promising clinical data from its completed ARTISTRY-1 phase 1/2 trial of nemvaleukin, showing positive antitumor activity in both monotherapy and combination therapy with pembrolizumab.
The trial, involving 286 patient...

Jaguar8

Nov 7, 2024 15:16

NEWS

$Mural Oncology (MURA.US)$
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Mural Oncology presented clinical and preclinical data at the 39th SITC Annual Meeting. The ARTISTRY-3 trial showed that less frequent IV dosing of nemvaleukin demonstrated tumor site-specific immune activation in ovarian cancer and mucosal melanoma patients. Preclinical data from IL-18 variants showed durable immune ...

Jaguar8

Nov 4, 2024 13:47

NEWS 13G

$Mural Oncology (MURA.US)$
Mural Oncology | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(4.90%)